Nanjing Cellnuo Biotechnology Co., Ltd.’s pharmaceutical division focuses on the development of diabetes biopharmaceuticals, using gene engineering to produce insulin and GLP-1 class biopharmaceuticals, and also developing other biopharmaceuticals. It actively explores new approaches to diabetes through stem cell therapy and intestinal microbiome therapy.

Another division of Cellnuo Biotechnology aims to provide global pharmaceutical companies, culture media companies, and research institutions with high-quality, high-stability recombinant proteins, enzymes, and other factor products and high-level technical services. The company can complete the process from gene synthesis to gram-level products and complete process schemes in as little as 2-3 weeks, especially specializing in the optimization of protein products with high technical difficulty and cost limitations.